Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Falk Heidenreich - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, DKMS Clinical Trials Unit (Author)
  • Bose Falk - , DKMS Clinical Trials Unit (Author)
  • Henning Baldauf - , DKMS Clinical Trials Unit (Author)
  • Carolin Massalski - , DKMS Life Science Lab gGmbH (Author)
  • Gesine Schäfer - , DKMS Life Science Lab gGmbH (Author)
  • Elke Rücker-Braun - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, DKMS Clinical Trials Unit (Author)
  • Heidi Altmann - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Jürgen Sauter - , DKMS Donor Center gGmbH (Author)
  • Ute V. Solloch - , DKMS Donor Center gGmbH (Author)
  • Vinzenz Lange - , DKMS Life Science Lab gGmbH (Author)
  • Friedrich Stölzel - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Christoph Röllig - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Jan M. Middeke - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Malte von Bonin - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Christian Thiede - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Kerstin Schäfer-Eckart - , Nuremberg Clinic (Author)
  • Carsten Müller-Tidow - , Heidelberg University  (Author)
  • Stefan W. Krause - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • Sabrina Kraus - , University of Würzburg (Author)
  • Martin Kaufmann - , Robert Bosch Krankenhaus Stuttgart (Author)
  • Mathias Hänel - , Klinikum Chemnitz gGmbH (Author)
  • Hubert Serve - , University Hospital Frankfurt (Author)
  • Andreas Neubauer - , University of Marburg (Author)
  • Martin Bornhäuser - , Department of Internal Medicine I, University Cancer Centre Dresden (Author)
  • Alexander H. Schmidt - , DKMS Clinical Trials Unit, DKMS Donor Center gGmbH (Author)
  • Johannes Schetelig - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, DKMS Clinical Trials Unit (Author)

Abstract

Immunogenetic association studies may give rise to new hypotheses on the immune surveillance of cancer. We hypothesized that certain combinations of killer immunoglobulin-like receptor (KIR) and HLA genotypes may enhance natural killer (NK) cell immunity against nascent acute myeloid leukemia (AML) and, thereby, lead to a skewed genotype distribution among patients. For this purpose, we analyzed KIR and HLA genotypes of 1767 German patients with AML and compared the results with that of the data of 51 890 German volunteers who had registered with German bone marrow donor file (DKMS). Patient samples were retrieved from the Collaborative Biobank and the biorepository of the Study Alliance Leukemia. All samples were genotyped with high-resolution amplicon-based next-generation sequencing. Because of the large number of controls, this study was very sensitive to detect the impact of KIR genotype. Knowledge on KIRs and their cognate HLA ligands allowed for testing of several hypotheses of NK cell–mediated endogenous leukemia surveillance. We did not find significant differences between the 2 cohorts in regard to the presence or absence of single KIR genes. When grouped based on telomeric or centromeric gene content, the major haplotypes A/A, A/B, and B/B were equally distributed among patients and control subjects. Using information on KIRs and their HLA ligands, we further tested receptor-ligand models and summation models without revealing markedly significant differences between patients and controls, albeit we observed a trend pointing at a minor protective effect of a low number of inhibitory KIR/KIR-ligand pairs. The results suggest that the KIR/KIR-ligand genotype has no effect on the susceptibility for the development of de novo AML.

Details

Original languageEnglish
Pages (from-to)2994-3004
Number of pages11
JournalBlood advances
Volume7
Issue number13
Publication statusPublished - 11 Jul 2023
Peer-reviewedYes

External IDs

PubMed 36689727

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Humans, Ligands, Genotype, Receptors, KIR/genetics, Leukemia, Myeloid, Acute/genetics, Case-Control Studies

Library keywords